View ValuationSirona Biochem 将来の成長Future 基準チェック /06現在、 Sirona Biochemの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.お知らせ • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.お知らせ • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.お知らせ • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.お知らせ • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.お知らせ • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.お知らせ • Jun 29Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEBSirona Biochem Corp. announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology. Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month. Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sirona Biochem は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:SRBC.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数7/31/20240-3-2-2N/A4/30/20240-2-2-2N/A1/31/20240-3-2-2N/A10/31/20230-3-2-2N/A7/31/20230-2-2-2N/A4/30/20231-2-2-2N/A1/31/20231-2-2-2N/A10/31/20221-4-2-2N/A7/31/20221-3-2-2N/A4/30/20220-4-2-2N/A1/31/20220-4-2-2N/A10/31/20210-2-2-2N/A7/31/20210-2-3-2N/A4/30/20210-3-3-3N/A1/31/20210-3-2-2N/A10/31/20200-4-2-2N/A7/31/20200-5-3-3N/A4/30/20200-5-3-3N/A1/31/20200-6-4-4N/A10/31/20190-5-4-4N/A7/31/20190-4-3-3N/A4/30/20191-2-2-2N/A1/31/20191-2-1-1N/A10/31/20181-1-1-1N/A7/31/20181-3-1-1N/A4/30/20181-4N/A-2N/A1/31/20181-4N/A-2N/A10/31/20170-4N/A-2N/A7/31/20170-3N/A-3N/A4/30/20170-3N/A-2N/A1/31/20170-3N/A-2N/A10/31/20160-3N/A-2N/A7/31/20160-3N/A-2N/A4/30/20160-3N/A-3N/A1/31/20160-4N/A-3N/A10/31/20150-4N/A-3N/A7/31/20150-3N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SRBC.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SRBC.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SRBC.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SRBC.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SRBC.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SRBC.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 01:02終値2026/05/07 00:00収益2024/07/31年間収益2023/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sirona Biochem Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Ellis AcklinFirst Berlin Equity Research GmbHJens HasselmeierFirst Berlin Equity Research GmbH
お知らせ • Apr 23Sirona Biochem Corp. announced that it expects to receive CAD 0.4 million in fundingSirona Biochem Corp. announced a non-brokered private placement that it will issue up to 400 unsecured convertible debentures units at an issue price of CAD 1,000 per unit for the gross proceeds of up to CAD 400,000 on April 22, 2025. Each Debenture Unit will have a face value of of CAD 1,120, consisting of CAD 1,000 in principal and CAD 120 in prepaid interest. The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, and such accrued interest will be paid semi-annually, in arrears. At the election of the Company, Prepaid Interest and Accrued Interest may be paid in cash or converted into Shares at a conversion price equal to the maximum Discounted Market Price equal to the maximum Discounted Market Price. The holder may, at its option, convert in full or in part, the Principal at any time prior to the maturity date, being the third anniversary of the issue date, into units of the Company at CAD 0.10 per Unit. Upon conversion of the Principal, Prepaid Interest and unpaid Accrued Interest, will be, at the election of the Company, either paid in cash or converted into Shares at the Interest Conversion Price. Each Unit will consist of one Share and one non-transferable share purchase warrant. Each Unit will consist of one Share and one non-transferable share purchase warrant at an exercise price of CAD 0.15 at any time prior to the Maturity Date. The Company shall have the right to redeem the Convertible Debentures prior to the Maturity Date at any time after 6 months from the issue date, by paying holders in cash the Face Value of the Convertible Debentures, together with all Prepaid and Accrued Interest and a redemption penalty payment of 8% of the Face Value. The closing of the Offering is subject to the receipt of necessary regulatory approvals, including the approval of the TSXV. The Convertible Debentures, Shares, Warrants and any Warrant Shares will be subject to a four month hold period under applicable securities laws and TSXV policies. The Company may pay eligible finders a fee in connection with the Offering.
お知らせ • Apr 22Sirona Biochem Corp. announced that it expects to receive CAD 3 million in funding from Promura GmbHSirona Biochem Corp. announced that it has entered into a investment agreement with Promura GmbH to issue unsecured convertible debentures for gross proceeds of CAD 3,000,000 on April 22, 2025. The debentures will accrue interest at the rate of 12%. The company plans to compensate finders by way of cash fees and warrants. The completion of the private placement is subject to customary conditions, including acceptance from the Toronto stock exchange venture. All securities issued will be subject to a hold period in accordance with TSXV and/or other regulatory requirements.
お知らせ • Apr 05Sirona Biochem Corp. announced that it has received CAD 0.1325 million in fundingOn April 4, 2024, Sirona Biochem Corp closed the transaction. The company has now issued 1,325,000 units at a price of CAD 0.10 per Unit for a gross proceeds of CAD 132,500. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024. No insiders participated in the private placement. No finders' fees were paid from the private placement.
お知らせ • Feb 02Sirona Biochem Corp. announced that it expects to receive CAD 1 million in fundingSirona Biochem Corp. announced that it has entered into a private placement of promissory note for aggregate principal amount of $1,000,000 on January 29, 2024. The transaction will include participation from new lender, 0906462 B.C. Ltd. The promissory note will interest at a rate of 12% per annum. The Company has agreed to, subject to TSX Venture Exchange approval.
お知らせ • Jan 27Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024Sirona Biochem Corp., Annual General Meeting, Mar 28, 2024.
お知らせ • Dec 12Sirona Biochem Corp. Initiates GlycoProteMim™? Trademark for Anti-Aging Molecule TFC-1326Sirona Biochem Corp. announced the trademarking of its anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim. This pivotal decision marks a significant milestone in Sirona Biochem's mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company's unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development, Sirona Biochem has developed GlycoProteMim (TFC-1326) into a powerful solution to reverse skin aging. The molecule has proven to be a game-changer in the fight against aging, offering a diverse range of permanent benefits. Sirona Biochem has begun the trademarking process through it's subsidiary TFChem and is actively engaging industry experts to chart the most effective course for commercializing GlycoProteMim™. This strategic move underscores the company's dedication to delivering a unique and transformative anti-aging solution to the $12.5 billion global anti-aging market. The choice to trademark GlycoProteMim goes beyond a mere formality; it stands as a testament to Sirona Biochem's commitment to revolutionizing beauty through scientific innovation. Through rigorous research and clinical trials, the company firmly believes that this name will soon be associated with timeless, radiant skin. Sirona Biochem is certain that GlycoProteMim will surpass the current gold standard, Retinol, in its ability to reverse skin aging. Unlike other products on the market, GlycoProteMim provides powerful results with exceptional tolerability.
お知らせ • Jun 29Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing At the ICGEBSirona Biochem Corp. announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology (ICGEB). The compounds, generated by Sirona's subsidiary TFChem, are aimed at expanding Sirona's existing library of antiviral drug candidates. The ICGEB, located in Trieste, Italy, will employ specialized assays developed at their Laboratory of Molecular Virology to screen a library of 18 newly produced candidates, for their potential to inhibit SARS-CoV2. Spearheading the research program is Dr. Alessandro Marcello, a globally recognized authority in Human Virology. Building upon the previous screening results of the initial 20 compounds, these newly selected candidates hold significant promise. Testing is slated to commence within the next month. Sirona Biochem remains committed to advancing the program on antiviral research and remains optimistic about the potential impact these new compound candidates may have in combatting viral diseases.